Risk of ischemic stroke with the use of risperidone, quetiapine and olanzapine in elderly patients: A population-based, case-crossover study

Journal of Psychopharmacology

Volumn 27, Issue 7, 2013, Pages 638-644

  Shin, Ju Young ^a   Choi, Nam Kyong ^b   Jung, Sun Young ^a   Lee, Joongyub ^b   Kwon, Jun S ^c   Park, Byung Joo ^a,b  

^a Korea Institute of Drug Safety and Risk Management   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University Hospital   (South Korea)

Author keywords

Atypical antipsychotics; case crossover; ischemic stroke; national health insurance claims database

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

AGED; ARTICLE; BRAIN ISCHEMIA; CASE STUDY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG USE; FEMALE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; ICD-10; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; TRANSIENT ISCHEMIC ATTACK;

ATYPICAL ANTIPSYCHOTICS; CASE-CROSSOVER; ISCHEMIC STROKE; NATIONAL HEALTH INSURANCE CLAIMS DATABASE;

AGE FACTORS; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; DIBENZOTHIAZEPINES; HUMANS; MIDDLE AGED; ODDS RATIO; RISK; RISPERIDONE; STROKE;

EID: 84879364740     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113482530     Document Type: Article

References (35)

1. Alexopoulos GS, Streim J, Carpenter D, et al. Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients. Using antipsychotic agents in older patients. J Clin Psychiatry. 2004 ; 65: S5 - S99
2. Evidence-based guidelines for the pharmacological treatment of schizophrenia: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011 ; 25: 567-620
3. Brodaty H, Ames D, Snowdon J, et al. Risperidone for sychosis of Alzheimer's disease and mixed dementia: Results of a double-blind, placebo-controlled trial. Int J Geriatr Psychiatry. 2005 ; 20: 1153-1157
4. Burke AD, Tariot PD. Atypical antipsychotics in the elderly: A review of therapeutic trends and clinical outcomes. Expert Opin Pharmacother. 2009 ; 10: 2407-2414
5. Deberdt WG, Dysken MW, Rappaport SA, et al. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry. 2005 ; 13: 722-730
6. Delaney JA, Suissa S. The case-crossover study design in pharmacoepidemiology. Stat Methods Med Res. 2009 ; 18: 53-65
7. Devanand DP, Marder K, Michaels KS, et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry. 1998 ; 155: 1512-1520
8. Donnan GA, Fisher M, Macleod M, et al. Stroke. Lancet. 2008 ; 371: 1612-1623
9. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: Self controlled case series study. Brit Med J. 2008 ; 337: a1227
10. Finkel S, Kozma C, Long S, et al. Risperidone treatment in elderly patients with dementia: Relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr. 2005 ; 17: 617-629
11. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: A critical overview. CMAJ. 2005 ; 172: 1703-1711
12. Herrmann N, Mamdani M, Lanctot KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry. 2004 ; 161: 1113-1115
13. Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006 ; 20: 389-409
14. Kales HC, Zivin K, Kim HM, et al. Trends in antipsychotic use in dementia 1999-2007. Arch Gen Psychiatry. 2011 ; 68: 190-197
15. Kinon BJ, Gilmore JA, Liu H, et al. Hyperprolactinemia in response to antipsychotic drugs: Characterization across comparative clinical trials. Psychoneuroendocrinology. 2003 ; 28: S69 - S82
16. Kleijer BC, van Marum RJ, Egberts ACG, et al. Risk of cerebrovascular events in elderly users of antipsychotics. J Psychopharmacol. 2009 ; 23: 909-914
17. McConville B, Sorter M. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. J Clin Psychiatry. 2004 ; 65: S20 - S29
18. Maclure M. The case-crossover design: A method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991 ; 133: 144-153
19. Maclure M, Mittleman MA. Should we use a case-crossover design?. Annu Rev Public Health. 2000 ; 21: 193-221
20. Mazzucco S, Cipriani A, Barbui C, et al. Antipsychotic drugs and cerebrovascular events in elderly patients with dementia: A systematic review. Mini Rev Med Chem. 2008 ; 8: 776-783
21. Moretti R, Torre P, Antonello R, et al. Olanzapine as a possible treatment of behavioral symptoms in vascular dementia: Risks of cerebrovascular events. J Neurol. 2005 ; 252: 1186-1193
22. Mowat D, Fowlie D, Macewan T. Csm warning on atypical psychotics and stroke may be detrimental for dementia. Brit Med J. 2004 1262 ; 328 :
23. Sacchetti E, Trifiro G, Caputi A, et al. Risk of stroke with typical and atypical anti-psychotics: A retrospective cohort study including unexposed subjects. J Psychopharmacol. 2008 ; 22: 39-46
24. Sacchetti E, Turrina C, Cesana B, et al. Timing of stroke in elderly people exposed to typical and atypical antipsychotics: A replication cohort study after the paper of Kleijer, et al. J Psychopharmacol. 2010a ; 24: 1131-1132
25. Sacchetti E, Turrina C, Valsecchi P. Cerebrovascular accidents in elderly people treated with antipsychotic drugs: A systematic review. Drug Saf. 2010b ; 33: 273-288
26. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: Meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006a ; 14: 191-210
27. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006b ; 355: 1525-1538
28. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA. 1997 ; 278: 1363-1371
29. Smith DA, Beier MT. Association between risperidone treatment and cerebrovascular adverse events: Examining the evidence and postulating hypotheses for an underlying mechanism. J Am Med Dir Assoc. 2004 ; 5: 129-132
30. Tariot PN, Schneider L, Katz IR, et al. Quetiapine treatment of psychosis associated with dementia: A double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry. 2006 ; 14: 767-776
31. Wada-Isoe K, Wakutani Y, Urakami K, et al. Elevated interleukin-6 levels in cerebrospinal fluid of vascular dementia patients. Acta Neurol Scand. 2004 ; 110: 124-127
32. Wallaschofski H, Donne M, Eigenthaler M, et al. PRL as a novel potent cofactor for platelet aggregation. J Clin Endocrinol Metab. 2001 ; 86: 5912-5919
33. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005 ; 353: 2335-2341
34. Wooltorton E. Olanzapine (Zyprexa): Increased incidence of cerebrovascular events in dementia trials. CMAJ. 2004 ; 170: 1395
35. Zhong KX, Tariot PN, Mintzer J, et al. Quetiapine to treat agitation in dementia: A randomized, double-blind, placebo-controlled study. Curr Alzheimer Res. 2007 ; 4: 81-93